About INT
Integrated Nanotherapeutics (INT) is a biotech company in Vancouver, Canada focused on using nanotechnology to uncover and maximize the therapeutic potential of many drugs.
Our proprietary drug delivery platform technology can deliver any type of drug modality in lipid nanoparticles (LNPs), either alone or in combination, to disease tissues and cells. The outcome is safer and more effective medicines that improve human health. In addition, we are advancing a therapeutic platform that induces antigen-specific tolerance to treat autoimmune diseases.
Our People
Integrated Nanotherapeutics is founded by a team of world-class scientists with multi-disciplinary skills in basic science, preclinical research, drug development, and commercialization of therapeutics. We have collectively over 100 years of experience in lipid nanoparticle (LNP) science and drug development. Our founding team and scientists have contributed to 5 approved LNP drugs (out of a total of 14). These include Abelcet®, Myocet®, Marqibo®, Onpattro® and Comirnaty®.
Our Technology Platforms
Drug Delivery Platform
Our versatile drug delivery platform allows the incorporation of virtually any small molecule and/or biologic into lipid nanoparticles (LNPs).
Immune Tolerance Platform
Our modular immune tolerance platform enables the development of therapies to treat many immune diseases including type 1 diabetes, MS and allergy.
Partnering
We welcome partnering opportunities with academic and industry groups. INT has developed a broad IP portfolio focused on the use of LNPs for delivery of small molecules, and macromolecules such as nucleic acids and peptides.
We have a solid track record of successfully working with local and international partners to advance their preclinical assets. With deep understanding of drug development process from discovery to regulatory approval, we have formed long-lasting relationships with our partners.
Email us at bd@integratedntx.com to learn more about how our team and technologies can help you reach your drug development goals.